

## Erratum

*Corrected Erratum (supersedes the previous version, published in the January 2000 issue)*

In the October 1998 issue, there were two table errors in the article “Prenatal Screening for Cystic Fibrosis Carriers: An Economic Evaluation,” by Rowley et al. (63: 1160–1174). In the last row of table 5, the difference in the marginal cost per QALY should be “\$8,290.” Also, table 9, which compares the marginal cost per QALY for selected preventive measures, may be misleading, since the authors of the cited references used two different methods of calculation. The values for antepartum Rh immunization, T<sub>4</sub> thyroid screening, phe-

nylketonuria screening, and school tuberculin screening were derived simply by dividing the program costs by the number of QALYs that the program produced. In contrast, the other analyses, including our evaluation of prenatal cystic fibrosis–carrier screening and the evaluations of pneumococcal vaccine and of postmenopausal estrogen replacement, considered also the costs incurred by the number of those *not* screened. This latter methodology is the preferred method, since it makes a comparison, often with existing practice; however, since it often entails high costs for the unscreened group, it may yield a cost-effectiveness ratio that is more favorable to screening. The *Journal* regrets these errors.